Obtaining sequence information of target multivalent immunoglobulin single variable domains
A computer-implemented method efficiently sequences multivalent ISVs by generating candidate sequences and constructing matrices to align and trim reads, addressing the challenges of large sequence sizes and repetitive sequences, achieving rapid and accurate sequencing results.
Patent Information
- Application Number
- JP2024529915
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-22
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-19
AI Technical Summary
Obtaining sequence information for multivalent immunoglobulin single variable domains (ISVs) is challenging due to the large size of the sequences, which conventional sequencing techniques struggle to handle, and combining fragment sequences is time-consuming and difficult due to the presence of repeating sequences.
A computer-implemented method that receives sequence information for multiple component ISVs, generates candidate sequences, identifies hit sequences through pattern matching, and constructs consensus and assembly matrices to rapidly determine the sequence information of target multivalent ISVs, even with errors, by trimming and aligning reads to ensure accuracy.
Enables rapid and accurate identification of sequence information for multiple target multivalent ISVs, reducing errors and improving the probability of accurate sequencing results.
Smart Images

Figure 2024543109000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to obtaining sequence information for target multivalent immunoglobulin single variable domains (ISVs) based on sequence information received for multiple component ISVs. [Background technology]
[0002] Obtaining sequence information, e.g., DNA sequences, of multivalent ISVs is a challenging task. For example, sequence information of multivalent immunoglobulin single variable domains (ISVs) is usually too large to be sequenced at once by conventional sequencing techniques. Techniques for sequencing fragments of a multivalent ISV to obtain the sequence of the entire multivalent ISV require combining the sequence information (or parts thereof) of each fragment, which is a time-consuming and challenging task, e.g., because many repeated sequences may exist within each of the sequenced fragments. Summary of the Invention [Means for solving the problem]
[0003] According to a first aspect of the present disclosure, a computer-implemented method for obtaining sequence information for each of a plurality of target multivalent immunoglobulin single variable domains (ISVs) is described, the method comprising: receiving sequence information for each of a plurality of component ISVs, each of the target multivalent immunoglobulin single variable domains (ISVs) comprising a plurality of component ISVs; generating a set of candidate sequences for the multivalent ISVs based on the received sequence information; obtaining a plurality of groups of reads of sequencing information, each group of reads corresponding to a particular target multivalent ISV of the plurality of target multivalent ISVs; and, for each lead in the group of reads, identifying one or more hit candidate sequences from the set of candidate sequences, each of the one or more hit candidate sequences comprising a match with a corresponding portion of the read; and identifying the hit candidate sequences, the reads, and generating a consensus matrix for each of the candidate hit sequences using the reads, and one or more sequences derived from the reads, where the consensus matrix indicates a consensus between the candidate hit sequences, the reads, and one or more sequences derived from the reads for each position among the multiple positions of the alignment sequence; generating an assembly matrix for each of the candidate hit sequences for each of the read groups based on the consensus matrix of each read in the read group; and identifying sequence information for each target multivalent ISV based on the one or more assembly matrices identified for the read group corresponding to the target multivalent ISV.
[0004] This allows for the sequence information of each of multiple target multivalent ISVs to be identified in an automated and rapid manner, for example identifying the sequence information of 96 clones in a few minutes.
[0005] The read may include a character code for each position among the positions of the read. Each character code specifies either a character code for a primary base or an ambiguity character code. For a read, identifying one or more hit candidate sequences from the set of candidate sequences may include removing one or more character codes from an end of the read to generate a truncated read for each iteration among the multiple iterations. The identifying may further include performing a pattern matching process between the truncated reads of the iterations and each candidate sequence. The identifying may further include adding the particular candidate sequence to the one or more hit candidate sequences if the truncated read of an iteration matches the particular candidate sequence.
[0006] This allows for example for sequence information of each target multivalent ISV to be identified even in the presence of sequencing errors or mistakes; by removing a small number of character codes at a time, the number of candidate sequence hits in each iteration is reduced, thus increasing the likelihood of identifying accurate sequence information of the target multivalent ISVs.
[0007] A read may specify a sequencing quality for each position. For a read, identifying one or more hit candidate sequences from a set of candidate sequences may include receiving a cutoff parameter, removing one or more character codes from the read each having a sequencing quality lower than a value specified by the cutoff parameter, identifying a start position of the read, and identifying a trimmed read including removing character codes from the read before the start position, identifying a position of the read that first specifies an ambiguity character code, and removing character codes from the read starting from the specified position to the end position of the read.
[0008] This can help ensure that the leads are of sufficiently high quality.
[0009] Each candidate sequence in the hit candidate sequences may include a respective match portion corresponding to each read in the read pool.
[0010] This can help ensure that the candidate sequence hits are valid for each read.
[0011] The alignment sequence can be identified by performing a multiple sequence alignment, MSA, between the hit candidate sequence, the read, and one or more sequences derived from the read. The multiple sequence alignment can be configured to align each of the hit candidate sequence, the read, and one or more sequences derived from the read without introducing any gaps in the alignment sequence. This can help to find a "perfect" alignment, and thus obtain more meaningful results (i.e., less likely due to chances due to the insertion of gaps) in the consensus matrix.
[0012] The one or more sequences derived from the reads may include at least one of the following: trimmed reads, in which one or more letter codes of the reads have been removed, each of which has a sequencing quality lower than a value specified by the received cutoff parameters; and base call sequences, in which positions of the reads with ambiguity letter codes have been replaced with the letter code of the primary base.
[0013] Each group in the multiple groups of reads may include one or more forward reads for each target multivalent ISV in the group and one or more reverse reads for each target multivalent ISV.
[0014] Generating a set of candidate sequences for multivalent ISVs based on the received sequence information may include receiving sequence information of one or more linkers, receiving an indication of a specific restriction enzyme recognition site, and using the sequencing information of the one or more linkers and the indication of the specific restriction enzyme recognition site to generate a set of candidate sequences for multivalent ISVs.
[0015] The sequence matrix may include a score for each major base letter code in the set of major base letter codes at each position in the plurality of positions in the aligned sequences. The assembly matrix may include, for each read in the read population and for each position in the aligned sequences, either the letter code of the major base or an empty symbol indicating that no letter code of the major base could be determined for that position of the read.
[0016] Each component ISV may be selected from a VL, a VH, a VHH, a humanized VHH, and a camelized HV. Each component ISV may be a monovalent ISV.
[0017] The sequence information of each target multivalent ISV may comprise a nucleic acid sequence. The sequence information of each component ISV may comprise a nucleic acid sequence. The nucleic acid sequence may be a DNA sequence.
[0018] According to another aspect of the present specification, an apparatus is described that includes one or more processors configured to perform any one or more of the methods described herein.
[0019] According to another aspect of the present specification, a computer-readable storage medium is described that includes instructions that, when executed by one or more processors, cause the one or more processors to perform any one or more of the methods described herein.
[0020] In order that the invention may be more easily understood, embodiments thereof will now be described, by way of example only, with reference to the accompanying drawings in which: [Brief description of the drawings]
[0021] [Figure 1] 1 shows an exemplary multivalent ISV. [Diagram 2] 1 shows a flow chart of an exemplary method for obtaining sequence information of multivalent ISVs. [Diagram 3] 1 shows an exemplary portion of a consensus matrix for target multivalent ISVs. [Figure 4]1 shows an exemplary portion of an assembly matrix of target multivalent ISVs. [Diagram 5] Exemplary DNA sequences identified for each of the two multivalent ISVs are shown. [Figure 6] Exemplary amino acid sequences identified for each of the two multivalent ISVs are shown. [Figure 7] FIG. 1 is a schematic diagram of a system / apparatus for carrying out the methods described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] Various exemplary implementations described herein relate to systems and methods for obtaining sequence information (e.g., nucleic acid sequences, such as DNA sequences) of multivalent ISVs. In particular, the described systems and methods generate a set of theoretical sequences of a library of multivalent ISVs based on sequence information (e.g., DNA sequences) of the component ISVs that form the multivalent ISVs. The theoretical sequences (which may also be referred to herein as theoretical constructs) are compared with sequencing results (i.e., reads) obtained for fragments of a multivalent ISV and one or more sequences derived from the sequencing results to identify sequence information of the multivalent ISV. In this way, sequence information of the ISVs is obtained in an automated and robust manner with high accuracy.
[0023] The library of target multivalent ISVs is derived from a plurality of component ISVs, which may include one or more monovalent ISVs, one or more bivalent ISVs, one or more trivalent ISVs, or any other component ISV for which sequence information for the entire component ISV is specified. In some embodiments, each of the component immunoglobulin single variable domains may be a monovalent ISV.
[0024] A library of target polyvalent ISVs is made from multiple component ISVs using standard techniques. For example, the genomic DNA (or cDNA) of each ISV is extracted and purified, then digested using physical or enzymatic techniques, e.g., using restriction enzymes, to generate smaller double-stranded fragments. Adapters (short double-stranded pieces of synthetic DNA) are then ligated to the ends of these digested DNA fragments. The DNA library is then clonally amplified to increase the signal detected from each target fragment during sequencing. During amplification, each DNA fragment in the library is immobilized on a bare or flow cell surface and amplified using PCR to generate identical clones. This amplification creates clusters of DNA, each originating from a single library fragment and representing one of the multiple component ISVs.
[0025] The DNA library of target multivalent ISVs is then sequenced using one of many sequencing methods well known to those skilled in the art, including high-throughput next-generation sequencing (NGS) methods, such as 454 pyrosequencing, ion torrent semiconductor sequencing, sequencing by ligation (SOLid), or Illumina sequencing. For example, DNA fragments can be placed into a well with a DNA polymerase and primers that hybridize to the 3' end of the template strand, and a perfectly complementary strand of each fragment is synthesized. Thus, the DNA sequences of the multiple component ISVs and one or more linkers that link the component ISVs (and / or shared regions) together can be obtained using multiple primers for sequencing, including, for example, one or more forward primers and / or one or more reverse primers, and a restriction enzyme.
[0026] For example, a library of target multivalent ISVs can be sequenced using one or more microplates, with each well of the microplate corresponding to a different combination of component ISVs and / or a different fragment of the multivalent ISV generated using different primers used for sequencing. As a specific example, a different 96-well plate can be used for each primer, with corresponding locations in each well plate corresponding to the same clone. For example, well A01 of the first plate can correspond to a clone sequenced using a forward primer, and well A01 of the second plate can correspond to the same clone sequenced using a reverse primer. Alternatively, one plate can be sequenced using different primers, where each clone is sequenced by a particular one of the various primers in different wells.
[0027] Figure 1 shows an exemplary targeted multivalent ISV 100. The multivalent ISV 100 shown in Figure 1 is a pentavalent ISV consisting of five monovalent ISVs 101, 102, 103, 104, 105 linked together by a linker 106. Each of the monovalent ISVs can be directed to a different site of the same target (i.e., antigen), or to a different target.
[0028] The term "immunoglobulin single variable domain" (ISV) is used interchangeably with "single variable domain" and defines an immunoglobulin molecule in which an antigen-binding site is present on, and formed by, a single immunoglobulin domain. This distinguishes immunoglobulin single variable domains from "conventional" immunoglobulins (e.g., monoclonal antibodies) or fragments thereof (e.g., Fab, Fab', F(ab')2, scFv, di-scFv), in which two immunoglobulin domains, in particular two variable domains, interact to form an antigen-binding site. Typically, in conventional immunoglobulins, a heavy chain variable domain (V H ) and the light chain variable domain (V L ) interact to form the antigen-binding site. In this case, V H and V LBoth complementarity determining regions (CDRs) of each gene contribute to the antigen-binding site, i.e., a total of six CDRs are involved in forming the antigen-binding site.
[0029] In view of the above definition, fragments of conventional four chain antibodies (e.g. IgG, IgM, IgA, IgD or IgE molecules known in the art), or Fab fragments, F(ab')2 fragments, Fv fragments such as disulfide-linked Fv or scFv fragments, or bispecific antibodies derived from such conventional four chain antibodies (all known in the art) are not usually considered as immunoglobulin single variable domains, because in these cases binding to the respective epitope of an antigen is usually not by one (single) immunoglobulin domain, but by a pair of (related) immunoglobulin domains such as light and heavy chain variable domains, i.e. the V of immunoglobulin domains which jointly bind to the respective epitope of the antigen. H -V L Because it happens in pairs.
[0030] In contrast, an immunoglobulin single variable domain can specifically bind to an epitope of an antigen without pairing with other immunoglobulin variable domains. The binding site of an immunoglobulin single variable domain is a single V H , single V HH or single V L It is formed by domains. Therefore, a single variable domain may be used with any light chain variable domain sequence (e.g., VV ... L -sequence) or a suitable fragment thereof, or a heavy chain variable domain sequence (e.g., H -sequence or V HH sequence) or a suitable fragment thereof. Immunoglobulin single variable domains (ISVs) include, for example, heavy chain ISVs, such as camelized ISVs. H or humanized V HH Contains V H,V HH In one embodiment, this can be a camelized V H or humanized V HH Contains V HH The heavy chain ISVs can be derived from traditional four chain antibodies or from heavy chain antibodies.
[0031] For example, an immunoglobulin single variable domain can be a single domain antibody (or an amino acid sequence suitable for use as a single domain antibody), a "dAb" or dAb (or an amino acid sequence suitable for use as a dAb), a Nanobody® ISV (as defined herein, HH The amino acid sequence may be, for example, a C-terminal fragment of a C-terminal end of a sRNA, ... In particular, the immunoglobulin single variable domain is a Nanobody® ISV (e.g., a humanized VSV). HH Or camelization V H Contains V HH ) or a suitable fragment thereof. [Note: Nanobody® and Nanobodies® are registered trademarks of Ablynx NV.] "VHH domain" means V HH s, V HH Antigen fragments, and V HH Also known as antibodies, they were originally described as antigen-binding immunoglobulin variable domains of "heavy chain antibodies" (i.e., "antibodies without light chains"; Hamers-Casterman et al. Nature 363:446-448 (1993)). HH The term "variable domain" refers to the heavy chain variable domains present in a conventional four-chain antibody (heavy chain variable domains, herein referred to as "V H domains”) present in conventional four-chain antibodies (herein referred to as “V L The domain was chosen to distinguish it from the domains that are called "domains." HHFor further description of , see the review article by Muyldermans (Reviews in Molecular Biotechnology 74:277-302, 2001).
[0032] The generation of immunoglobulin sequences such as VHHs has been extensively described in various published literature, including WO 94 / 05678, Hamers-Casterman et al. 1993 and Muyldermans et al. 2001 (Reviews in Molecular Biotechnology 74:277-302, 2001). In these methods, camelids are immunized with a target antigen to elicit an immune response against the target antigen. The repertoire of VHHs resulting from the immunization is further screened to select VHHs that bind to the target antigen.
[0033] In these instances, antibody production requires purified antigen for immunization and / or screening. Antigens can be purified from natural sources or during recombinant production. Immunization and / or screening for immunoglobulin sequences can be performed using peptide fragments of such sources.
[0034] Immunoglobulin sequences of different origins, including mouse, rat, rabbit, donkey, human, and camelized immunoglobulin sequences, can be sequenced by the methods described herein. Also, fully human, humanized, or chimeric sequences can be sequenced by the methods described herein. For example, camelid immunoglobulin sequences and humanized camelid immunoglobulin sequences, or camelized domain antibodies, such as camelized dAbs described by Ward et al. (see, e.g., WO 94 / 04678 and Riechmann, Febs Lett., 339:285-290, 1994 and Prot. Eng., 9:531-537, 1996), can be sequenced by the methods described herein. Additionally, ISVs can be fused to form multivalent and / or multispecific constructs (one or more V HHFor multivalent and multispecific polypeptides containing domains and their formulations, see Conrath et al., J. Biol. Chem., Vol. 276.10.7346-7350, 2001, as well as, for example, WO 96 / 34103 and WO 99 / 23221).
[0035] "Humanized V HH " is a naturally occurring V HH domain, but "humanized," i.e., the naturally occurring V HH One or more amino acid residues in the amino acid sequence (and particularly in the framework sequences) of the sequence are replaced with a V H The humanized V domain may comprise an amino acid sequence substituted with one or more of the amino acid residues (e.g., as described above) occurring at the corresponding positions in the V domain. This can be carried out in a manner well known per se, as will be clear to the skilled artisan, for example based on the prior art (e.g., WO 2008 / 020079). Again, such a humanized V domain may be substituted with one or more of the amino acid residues (e.g., as described above) occurring at the corresponding positions in the V domain. HH It should be noted that the VHH domain-containing polypeptide may be obtained by any conventional method known per se and is therefore not strictly limited to polypeptides obtained using naturally occurring VHH domain-containing polypeptides as starting material.
[0036] "Camelization V H " is a naturally occurring V H The amino acid sequence of the V domain corresponds to that of the naturally occurring V from a conventional four-chain antibody, but has been "camelized", i.e. H One or more amino acid residues in the amino acid sequence of the domain are replaced by the V HH The term "camelization" includes an amino acid sequence in which one or more of the amino acid residues occurring in the corresponding positions in the V domain are substituted. This can be carried out in a manner known per se, as will be clear to the skilled artisan, for example as described in the prior art (e.g. Davies and Riechman (1994 and 1996) supra). Such "camelization" substitutions, as defined herein, can be carried out by the addition of one or more of the amino acid residues occurring in the corresponding positions in the V domain. H-V L They are inserted at the positions of amino acids that form and / or are present at interfaces and / or so-called camelid hallmark residues (see, for example, WO 94 / 04678 and Davies and Riechmann, supra (1994 and 1996)). H V, which is used as a starting material or starting point for generating or designing H The sequence is V H Sequences, e.g., V H Array, e.g. V H 3 sequence. However, such camelized V H can be obtained by any suitable method known per se, and therefore naturally occurring V as starting material. H It should be noted that the polypeptide obtained using the polypeptide containing the domain is not strictly limited.
[0037] The structure of an immunoglobulin single variable domain sequence can be considered to consist of four framework regions ("FRs"), which are referred to in the art and herein as "framework region 1" ("FR1"), "framework region 2" ("FR2"), "framework region 3" ("FR3"), and "framework region 4" ("FR4"), respectively, interrupted by three "complementarity determining regions" ("CDRs"), which are referred to in the art and herein as "complementarity determining region 1" ("CDR1"), "complementarity determining region 2" ("CDR2"), and "complementarity determining region 3" ("CDR3"), respectively.
[0038] In such immunoglobulin sequences, the framework regions may be any suitable framework region sequence, and examples of suitable framework sequences will be clear to the skilled person, e.g. from standard handbooks and on the basis of the further disclosure and prior art contained herein.
[0039] The framework sequences are immunoglobulin framework sequences or framework sequences derived from immunoglobulin framework sequences (e.g., by humanization or camelization) (as appropriate combinations). For example, the framework sequences may be those of a light chain variable domain (e.g., V L -sequence) and / or heavy chain variable domain (e.g., V H -sequence or V HH In one particular embodiment, the framework sequence is derived from the V HH -framework sequences derived from conventional V sequences (wherein said framework sequences are optionally partially or fully humanized) or camelized (as defined herein) H It is one of the arrays.
[0040] In particular, the framework sequences present in the ISV sequences used in the methods described herein may include one or more Hallmark residues (as defined herein), and the ISV sequence may be, for example, a humanized VSV. HH or Camelization V H Contains V HH Non-limiting examples of (suitable combinations of) such framework sequences will become apparent from the disclosure herein below. V H Domain and V HH The total number of amino acid residues in a domain will usually be in the range of 110 to 120, often 112 to 115. It should be noted, however, that shorter and longer sequences may also be suitable for the purposes described herein. However, it should be noted that the ISVs contained in the multivalent ISV polypeptide sequenced by the methods of the present application are not limited as to the origin of the ISV sequence (or of the nucleotide sequence used to represent it) or the manner in which the ISV sequence or nucleotide sequence is (or has been) generated or obtained. Thus, the ISV sequence may be a naturally occurring sequence (from any suitable species) or a synthetic or semi-synthetic sequence. In specific, but non-limiting embodiments, the ISV sequence is a naturally occurring sequence (from any suitable species) or a synthetic or semi-synthetic sequence, including humanized (as defined herein) immunoglobulin sequences (e.g., partially or fully humanized mouse or rabbit immunoglobulin sequences, and in particular partially or fully humanized VHV sequences). HH sequences), "camelized" (as defined herein) immunoglobulin sequences (and in particular camelized V H ISVs include ISVs derived by techniques such as immunoglobulin sequence engineering techniques well known to those skilled in the art, as well as ISVs derived from synthetic, random, or naturally occurring immunoglobulin sequences, affinity maturation (e.g., starting from synthetic, random, or naturally occurring immunoglobulin sequences), CDR grafting, veneering, joining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar immunoglobulin sequence engineering techniques, or any suitable combination of any of the foregoing.
[0041] Likewise, the nucleotide sequence may be a naturally occurring nucleotide sequence or a synthetic or semi-synthetic sequence, for example a sequence isolated by PCR from a suitable naturally occurring template (e.g. DNA or RNA isolated from a cell), a nucleotide sequence isolated from a library (and in particular an expression library), a nucleotide sequence prepared by mutagenesis (using any suitable technique known per se, such as mismatch PCR) into a naturally occurring nucleotide sequence, a nucleotide sequence prepared by PCR using overlapping primers, or a nucleotide sequence prepared using DNA synthesis techniques known per se.
[0042] In general, Nanobody® ISVs (especially (partially) humanized VSVs)HH Sequence and camelized V H V containing arrays HH A Nanobody® ISV (a sequence) may be characterized by the presence of one or more "hallmark residues" (also as further described herein) in one or more framework sequences (as described herein). Thus, in general, a Nanobody® ISV may be defined as an immunoglobulin sequence having the following (general) structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 wherein FR1-FR4 refer to framework regions 1-4, respectively, CDR1-CDR3 refer to complementarity determining regions 1-3, respectively, and one or more of the hallmark residues are as further defined herein. Specifically, a Nanobody® ISV can be an immunoglobulin sequence having the following (general) structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 wherein FR1-FR4 refer to framework regions 1-4, respectively, CDR1-CDR3 refer to complementarity determining regions 1-3, respectively, and one or more of the hallmark residues are as further defined herein. More specifically, a Nanobody® ISV can be an immunoglobulin sequence having the following (general) structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 where FR1 to FR4 refer to framework regions 1 to 4, respectively, and CDR1 to CDR3 refer to complementarity determining regions 1 to 3, respectively; One or more of the amino acid residues at positions 11, 37, 44, 45, 47, 83, 84, 103, 104, 108 according to the Kabat numbering are selected from the hallmark residues set out in Table A below.
[0043] [Table 1]
[0044] As used herein, VHH is a heavy chain-only antibody (HcAB), approximately 15 kDa in size, naturally occurring in camelids (HVV from camel, alpaca, dromedary, llama) and cartilaginous fish (VNAR from shark). VHH corresponds to the variable region of a heavy chain antibody.
[0045] ISVs have advantages over conventional antibodies: they are approximately one-tenth the size of an IgG molecule, and as a result, properly folded, functional ISVs can be produced by in vitro expression while achieving high yields. Furthermore, ISVs are highly stable, resistant to the action of proteases, and can be easily engineered into bivalent or multivalent forms.
[0046] As used herein, the term "monovalent ISV" refers to a compound that comprises or consists essentially of a single ISV.
[0047] As used herein, the term "multivalent ISV" refers to a compound having two or more ISVs linked within a single branch.
[0048] In general, the term "multivalent" refers to the presence of multiple ISVs in a polypeptide. In one embodiment, the polypeptide is "bivalent", i.e., comprises or consists of two ISVs. In one embodiment, the polypeptide is "trivalent", i.e., comprises or consists of three ISVs. In another embodiment, the polypeptide is "tetravalent", i.e., comprises or consists of four ISVDs. The polypeptides sequenced in the methods described herein can therefore be "bivalent", "trivalent", "tetravalent", "pentavalent", "hexavalent", "heptavalent", "octavalent", "nonevalent", etc., i.e., the polypeptide comprises or consists of 2, 3, 4, 5, 6, 7, 8, 9, etc. ISVs, respectively. In one embodiment, the multivalent ISV polypeptide is trivalent. In another embodiment, the multivalent ISV polypeptide is tetravalent. In yet another embodiment, the multivalent ISV polypeptide is pentavalent.
[0049] In one embodiment, the multivalent ISV polypeptide can also be multispecific. The term "multispecific" refers to binding to multiple different target molecules (also called antigens). The multivalent ISV polypeptide can therefore be "bispecific", "trispecific", "tetraspecific", etc., i.e., capable of binding to two, three, four, etc. different target molecules, respectively.
[0050] For example, the polypeptide may be bispecific-trivalent, e.g., a polypeptide comprising or consisting of three ISVs, where two ISVs bind to a first target and one ISV binds to a second target that is different from the first target. In another example, the polypeptide may be trispecific-tetravalent, e.g., a polypeptide comprising or consisting of four ISVs, where one ISV binds to a first target, two ISVs bind to a second target that is different from the first target, and one ISV binds to a third target where the first and second targets are different. In yet another example, the polypeptide may be trispecific-pentavalent, e.g., a polypeptide comprising or consisting of five ISVs, where two ISVs bind to a first target, two ISVs bind to a second target that is different from the first target, and one ISV binds to a third target where the first and second targets are different.
[0051] In one embodiment, the multivalent ISV polypeptide can also be multiparatopic. The term "multiparatopic" refers to binding to multiple different epitopes on the same target molecule (also called antigen). Thus, the multivalent ISV polypeptide can be "biparatopic", "triparatopic", etc., i.e., each capable of binding to two, three, etc. different epitopes on the same target molecule.
[0052] As used herein, the term "linker" refers to a peptide that fuses two or more (poly)peptides (e.g., ISVs, common regions as defined herein, etc.) into a single molecule. The use of linkers to join two or more (poly)peptides is well known in the art. Another exemplary peptide linker is shown in Table A. One class of frequently used peptide linkers is known as "Gly-Ser" or "GS" linkers. These are linkers that consist essentially of glycine (G) and serine (S) residues, and typically contain one or more repeats of a peptide motif, such as a GGGGS (SEQ ID NO:2) motif (e.g., a repeat of the formula (Gly-Gly-Gly-Gly-Ser) n where n can be 1, 2, 3, 4, 5, 6, 7 or more). Some frequently used examples of such Gs linkers are the 9GS linker (GGGGSGGGS, SEQ ID NO:5), the 15GS linker (n=3) and the 35GS linker (n=7). See, e.g., Chen et al. Adv. Drug Deliv. Ref. 2013 Oct 15; 65(10); 1357-1369 and Klein et al., Protein Eng. Des. Sel. (2014) 27(10); 325-330.
[0053] [Table 2]
[0054] As used herein, the term "common region" refers to a region that may be present in each of multiple target multivalent ISVs. H , V L、 It may contain cytokines or other proteins / peptides, which may be attached to the linker. The common region may be used to extend the half-life of the multivalent ISV in vivo.
[0055] 2 shows a flow chart of an exemplary method 200 for obtaining sequence information of multivalent ISVs. Method 200 generates sequence information for each target multivalent ISV in a library of target multivalent ISVs, the library of target multivalent ISVs being generated from multiple component ISVs as described above.
[0056] In step 2.1, sequence information for each of a plurality of component ISVs is received. Each target multivalent ISV includes a plurality of the plurality of component ISVs. The sequence information for each component ISV may be a nucleic acid sequence, such as a DNA sequence or an RNA sequence, or the sequence information may be an amino acid sequence. The sequence information may be provided in the form of a FASTA file, a raw data file (e.g., ABIF file format), or a data stream derived from a sequencing device for each component ISV.
[0057] Additional information for generating a set of candidate sequences for a library of target multivalent ISVs may also be received. For example, sequence information for each of one or more linkers may be received. Sequence information for each of one or more common regions may be received. The sequence information may be a nucleic acid sequence, such as a DNA sequence or an RNA sequence, or the sequence information may be an amino acid sequence. The sequence information may be provided in the form of a FASTA file for each linker. Sequence information for one or more flanking primers for each component ISV may also be received. Sequence information for one or more constant regions may also be received. An indication of specific restriction enzyme recognition sites used for cloning may also be received.
[0058] Thus, information can be received that reflects the molecules and compounds used to generate a library of target multivalent ISVs using cloning techniques, the received information being used to generate in silico a library of theoretical sequences for the multivalent ISVs.
[0059] In step 2.2, a set of candidate sequences for multivalent ISVs is generated based on the received sequence information. The set of candidate sequences is the set of all theoretical sequences of multivalent ISVs that can be created using the component ISVs and, if appropriate, linkers and common regions (each such theoretical sequence is also referred to as a theoretical construct). In some examples, the set of candidate sequences is identified from a fixed set of component ISVs (e.g., one ISV for each position of the multivalent ISV), but may be different linkers to identify the best linker combination of multivalent ISVs that include a fixed set of component ISVs. The set of candidate sequences is generated in a combinatorial manner, thereby ensuring that each possible theoretical construct is reflected in the set of candidate sequences. The set of candidate sequences includes sequence information for each of the theoretical constructs. The sequence information may be a nucleic acid sequence, such as a DNA sequence or an RNA sequence, or the sequence information may be an amino acid sequence. The sequence information for each theoretical construct may be stored in memory (e.g., in the form of a FASTA file) or otherwise retained.
[0060] In step 2.3, a plurality of groups of reads of sequencing information are obtained. Each group of reads corresponds to a particular target multivalent ISV. Each group of reads includes one or more forward reads of a particular target multivalent ISV and / or one or more reverse reads of the particular target multivalent ISV. Each read in the group of reads is obtained from sequencing a fragment of the same target multivalent ISV using a different primer. A forward read is a read obtained using a forward primer, and a reverse read is a read obtained using a reverse primer. Any suitable combination of forward reads and / or reverse reads can be used to form the group of reads. For example, a group of reads can consist of two or more forward reads, a group of reads can consist of two or more reverse reads, a group of reads can consist of one or more forward reads and one or more reverse reads, etc. Each group of the plurality of groups of reads can include reads obtained from the same combination of forward primers and / or reverse primers, for example, each group of the plurality of groups of reads can include the same number of forward and / or reverse reads.
[0061] A read is the sequencing information of a fragment of a polyvalent ISV as obtained by a sequencing machine. A read includes a letter code for each position among the positions of the read. Each letter code specifies either a major base letter code or an ambiguity letter code (e.g., an IUPAC ambiguity letter code). Therefore, a read may lack a base call, and sequencing can estimate the major base letter code for ambiguous / low quality reads. Each read may also include (or be otherwise associated with) a sequencing quality for each position of the read. The sequencing quality measures the confidence of the prediction of the letter code at that position.
[0062] A determination that a read belongs to a particular group of reads corresponding to a particular target multivalent ISV may be made based on metadata associated with the read. For example, the metadata may indicate a plate identifier, a sample identifier, and / or a well identifier, which may be used to group reads corresponding to the same target multivalent ISV. For example, using metadata associated with a read indicating a well identifier and a plate identifier, a read having an identifier for well C07 of a first plate is grouped together with a read for well C07 of a second plate.
[0063] Step 2.4 includes steps 2.4.1 and 2.4.2, which are performed for each lead in the group of leads. Furthermore, these steps are repeated for each group of leads. Steps 2.4.1 and 2.4.2 (and subsequent steps) may be performed in parallel, for example using a multi-core central processing unit (CPU). For example, each group of leads may be processed separately in the manner described below, with processing of leads within the same group being performed on the same CPU-thread.
[0064] In step 2.4.1, one or more candidate hit sequences are identified from the set of candidate sequences. Each of the one or more candidate hit sequences includes a match with every corresponding portion. Identification can be performed using a pattern matching process that compares the read (or a portion thereof) with each candidate sequence in the set of back sequences. Any suitable pattern matching process can be used, such as the Rabin-Karp algorithm, the Knuth-Morris-Pratt algorithm, the Boyer-Moore algorithm, etc.
[0065] The reads may first be pre-processed before the pattern matching process is performed. A start position may be specified for the read, and the character code of the read at the start position may be used. The start position may be pre-specified and constant, for example, the same start position may be used for all reads. Trimming the start of the read may help to remove residues associated with the cloning process that do not form part of the sequence information of the multivalent ISV. A position may be specified that first specifies an ambiguity letter code (e.g., an IUPAC ambiguity letter code) for the read, and the letter code having a position starting from the specified position to the end position of the read may be removed. By removing the letter code in this way, the ambiguity letter code is removed from the read. A cutoff parameter may be received, which indicates a desired quality level for the processed read. For each read, a different value of the cutoff parameter may be received. The read may be trimmed, which includes removing one or more letter codes of the read, each of which has a sequencing quality lower than the value specified by the cutoff parameter.
[0066] Candidate hit sequences for a read may be identified using multiple iterations. For example, in the first iteration, a comparison of the (pre-processed) read with each candidate sequence in the set of candidate sequences may be performed. A pattern matching process is performed to identify whether the read is included in any of the candidate sequences. Any candidate sequence that contains a portion that matches the read may be added to the candidate hit sequences for that read. The number of candidate hit sequences may be limited to the maximum number of candidate hit sequences. If the read is not included in any of the candidate sequences, the read may be trimmed by removing one or more character codes from the end of the read to generate a shortened read for the subsequent iteration. In some embodiments, one character code may be removed from the end of the read in each iteration. Removing fewer character codes in each iteration may increase the accuracy of the sequence information identified for the target multivalent ISVs.
[0067] The truncated reads of the iteration may be compared with each candidate sequence in the set of candidate sequences, for example, by performing a pattern matching process. If the truncated reads of the iteration match a particular candidate sequence, the particular candidate sequence may be added to one or more hit candidate sequences. The steps above may be repeated until one or more conditions are met. For example, the steps may be repeated until the number of hit candidate sequences reaches a maximum number and / or the truncated reads are shorter than a minimum length.
[0068] The hit candidate sequences of the reads in a group can be pruned to identify hit candidate sequences for the entire group of reads. For example, each set of hit candidate sequences identified for each read in the group of reads can be crossed. In other words, each candidate sequence in the hit candidate sequences includes a respective matching portion corresponding to each read in the group of reads. For example, if a particular candidate sequence includes a matching portion for the forward read of a group, but does not include a matching portion for the corresponding reverse read of the group, the particular candidate sequence can be removed from the hit candidate sequences.
[0069] In step 2.4.2, for each hit candidate sequence, a consensus matrix (or any other suitable data format, such as a list of lists, a dictionary, etc.) is generated using the hit candidate sequence, its read, and one or more sequences derived from the read. If the read has been pre-processed in step 2.4.1, the term read herein refers to the read before quality-based trimming is performed (i.e., the untrimmed read). The consensus matrix specifies the consensus between the hit candidate sequence, the read, and one or more sequences derived from the read for each position of the portions of the aligned sequence. The one or more sequences derived from the read include at least one of the following: trimmed reads from which one or more character codes, each of which has a sequencing quality lower than a value specified by the received cutoff parameter, have been removed, and base decision sequences from which positions with ambiguity character codes have been replaced with the character code of the primary base. The base decision sequences may be identified in any suitable manner.
[0070] The alignment sequence can be identified by performing multiple sequence alignment (MSA) between the hit candidate sequence, the read, and one or more sequences derived from the read. The alignment sequence is the sequence that best or fully aligns each of the sequences with each other. In some cases, the multiple sequence alignment can be configured to align each of the hit candidate sequence, the read, and one or more sequences derived from the read without introducing any gaps in the alignment sequence. In such a case, the alignment sequence can be the same as the hit candidate sequence. Any suitable MSA technique can be used, including, for example, dynamic programming, iterative, hidden Markov model, multiple sequence comparison by log expectation, etc.
[0071] The consensus matrix may include a score for each major base letter code from a set of major base letter codes at each position among the positions in the aligned sequences, where the score indicates how many sequences (i.e., those used to form the consensus matrix) match at a particular base letter code at a particular position.
[0072] Referring now briefly to FIG. 3, FIG. 3 shows an exemplary portion of a consensus matrix of aligned sequences of target multivalent ISVs. The exemplary consensus matrix shown in FIG. 3 represents a consensus matrix identified for forward reads. Additionally, FIGS. 3-6 show examples of methods and systems described herein in which a microplate is used to sequence target multivalent ISVs. For example, each of these figures shows an embodiment with respect to the sequence of well A01, which corresponds to a particular target multivalent ISV.
[0073] The columns of the consensus matrix are indexed with indices corresponding to positions in the aligned sequences, and the rows are indexed with the letter codes of the major bases. The exemplary consensus matrix in FIG. 3 is generated using a total of four sequences of the aligned sequences, namely the candidate hit sequence, the untrimmed forward read, and the two sequences derived from the forward read, the trimmed forward read, and the base call forward read. As a result, the maximum score that can be obtained for the letter code of a particular position is 4. As can be seen from FIG. 3, the maximum score is reached for positions in the aligned sequences up to position 801. Thus, for these positions, each of the sequences for the forward read matches with a particular letter code of the major base, indicating a high degree of confidence in the alignment.
[0074] In contrast, positions 1726, 1727, and 1728 in the aligned sequence only have a score of 1 for the highest scoring letter code at these positions, indicating that there are only candidate sequence hits in the aligned sequence and that the sequences on the forward reads cannot be used to validate the candidate sequences at these positions.
[0075] If the highest-scoring letter code at a particular position is higher than 1 but lower than the highest score (e.g., positions 823, 824), this indicates less confidence in the alignment. In such cases, the highest-scoring letter code and its corresponding score may be used in generating the assembly matrix.
[0076] Returning to Figure 2, in step 2.5, for each group of reads, an assembly matrix (or any other suitable data format, e.g., a list of lists, a dictionary, etc.) of each of the candidate hit sequences is generated based on the consensus matrix of each read in that group of reads. The results of the consensus matrices are combined to form an assembly matrix.
[0077] The assembly matrix may include, for each read in the group of reads and for each position in the aligned sequences, either a letter code for the major base or an empty symbol indicating that a letter code for the major base was not specified for that position of that read.
[0078] Referring now briefly to FIG. 4, FIG. 4 shows an exemplary portion of an assembly matrix for aligned sequences of target multivalent ISVs. The columns of the assembly matrix are indexed with indices corresponding to positions in the aligned sequences, and the rows are indexed with reads in the group of reads. The exemplary assembly matrix shown in FIG. 4 integrates the consensus matrix results determined from the forward read (denoted as "for_assembly") and each of the two reverse reads (denoted as "alb_rev_assembly" and "rev_assembly") for the target multivalent ISV corresponding to well A01. It will be appreciated that the group of reads may include other reads (e.g., other forward and / or reverse reads) and / or omit one of the forward and / or reverse reads.
[0079] Each of the entries in the assembly matrix is identified using the corresponding consensus matrix of the read associated with that entry. For example, the "for_assembly" entry at position 1 is identified using the consensus matrix of the forward read, and this consensus matrix is shown in FIG. 3. The highest scoring letter code at the first position of this consensus matrix (which in this example relates to the forward read) is the letter code "G", which reaches the maximum score (in this case, 4). As a result, the letter code "G" is inserted into the entry at the first position of "for_assembly". The other entries in the assembly matrix are identified in a similar manner, and the highest scoring letter code at each position of the consensus matrix of each read is typically inserted into the corresponding entry in the assembly matrix. If the highest score at a particular position in the consensus matrix is equal to 1 (e.g., position 1726 in Figure 3), then an empty symbol (shown as a dash in Figure 4) is inserted in its place to indicate that the letter code of the primary base could not be determined for that position in the read (e.g., as shown in the "for_assembly" entry at position 1726 in Figure 4).
[0080] As shown in the example of Figure 4, positions 517-525 of the aligned sequence are confirmed by both forward and reverse reads corresponding to "alb_rev_assembly", indicating that the hit candidate sequence corresponding to the assembly matrix is likely to be correct at these positions. Positions 762 and 764 are confirmed by all reads, indicating that the hit candidate sequence is more likely to be correct at these positions.
[0081] Returning to FIG. 2, in step 2.6, for each target multivalent ISV, sequence information is identified based on one or more assembly matrices identified for the group of reads corresponding to that target multivalent ISV. The sequence information may be a nucleic acid sequence, such as a DNA sequence or an RNA sequence, or the sequence information may be an amino acid sequence. The sequence information may be stored in the form of a FASTA file.
[0082] For each of the hit candidate sequences, an assembled sequence is identified based on the assembly matrix corresponding to the hit candidate sequence. The assembled sequence includes a letter code for each of the positions of the aligned sequences, which specifies either the letter code of the major base or the ambiguity letter code (e.g., IUPAC ambiguity letter code). For example, for a particular position in the assembly matrix, if the entry of each read at that position shows an empty symbol, N at that position in the assembled sequence can be identified. According to the IUPAC ambiguity letter code, this indicates that any of the major bases can be present at this position in the aligned sequence.
[0083] For a particular position in the assembly matrix, if each read entry shows the same letter code for a particular key base, then the letter code for this particular key base is identified for that position in the assembled sequence. For example, in position 762 in Figure 4, "T" is shown for all entries in the assembly matrix. As a result, the 762nd position in the assembled sequence is identified as "T".
[0084] For a position in the assembly matrix, multiple letter codes for the major bases may be specified. In this case, the scores of each of the multiple letter codes may be obtained, and a highest scoring letter code for that position in the assembled sequence may be identified. For example, consider a position in the assembly matrix that specifies "T" for the forward read, "A" for the reverse read, and "T" for another reverse read. The score of the "T" for the forward read may be determined from the score specified in the consensus matrix of the forward read for the letter code "T" at that position. Similarly, the score of the "A" for the reverse read and the score of the "T" for another reverse read may also be determined. The scores obtained from the consensus matrix may be used to determine the scores of the letter codes in the assembly matrix, for example, the score of the "T" for the forward read may be added to the score of the "T" for another reverse read. If the respective scores of the letter codes are equal, an ambiguity letter code is determined for that position in the assembled sequence based on the multiple letter codes for the major bases. In this example, an IUPAC ambiguity code of "W" (designated "A" or "T") can be identified for that position in the assembled sequence. Quality data of the sequencing results (e.g., per-base quality score (PCON) and / or PHRED score) can also be used to identify a letter code for a position in the assembly matrix. For example, if the quality data for a particular read indicates high sequencing quality for a particular letter code, then this letter code can be identified as the letter code for that position in the assembly matrix.
[0085] However, if one of the consensus matrices for a particular read has the maximum score for a particular letter code at that position (e.g., 4 in the example described with respect to Figure 3), then a particular key base letter code is identified for that position in the assembled sequence.
[0086] If there is only one hit candidate sequence, the assembled sequence corresponding to the hit candidate sequence is used to provide sequencing information for the target multivalent ISV. For example, the sequencing information can be the assembled sequence. Additionally or alternatively, the sequencing information can be derived from the assembled sequence, for example in the form of an amino acid sequence identified (i.e. translated) from the assembled sequence. In a situation where the number of hit candidate sequences is more than one, each assembled sequence can be compared with its corresponding hit candidate sequence. First, a pattern matching process can be performed to identify whether the assembled sequence is the same as its corresponding hit candidate sequence. If a particular assembled sequence exactly matches the candidate sequence, this particular assembled sequence is selected to provide the sequencing information of the target multivalent ISV. For example, the sequencing information can be the assembled sequence. Additionally or alternatively, the sequencing information can be derived from the assembled sequence, for example in the form of an amino acid sequence identified from the assembled sequence.
[0087] If none of the assembled sequences match the corresponding hit candidate sequence, the assembled sequence that most closely matches the hit candidate sequence is selected to provide the sequencing information of the target multivalent ISV. For example, sequence alignment techniques can be used to compare each assembled sequence with its corresponding hit candidate sequence. In particular, global pairwise alignment can be performed, for example, by dot matrix method, dynamic programming, and / or Word method. A score can be determined regarding how well the assembled sequence and its corresponding hit candidate sequence are aligned. The sequence alignment can be configured to perform the alignment without introducing any gaps in the alignment. The assembled sequence with the highest score can be selected to provide the sequencing information of the target multivalent ISV.
[0088] Figure 5 shows exemplary DNA sequences identified for each of the two multivalent ISVs. As shown in Figure 5, for the target multivalent ISV corresponding to well A01, a DNA sequence was identified that matches 100% with its corresponding hit candidate sequence (seq_95 of the set of candidate sequences). For the target multivalent ISV corresponding to well A02, the identified DNA sequence shows 87.7% identity with the most closely matching hit candidate sequence (seq_81) from the set of candidate sequences. The DNA sequences can be saved in any suitable format, for example, a FASTA file.
[0089] Figure 6 shows exemplary amino acid sequences identified for each of the two multivalent ISVs, corresponding to the DNA sequences shown in Figure 5. The amino acid sequences may be stored in any suitable format, for example a FASTA file.
[0090] 7 is a schematic diagram of a system / apparatus for performing the methods described herein. The illustrated system / apparatus is an example of a computing device. Those skilled in the art will appreciate that other types of computing devices / systems, such as distributed computing systems, may alternatively be used to perform the methods described herein.
[0091] The device (or system) 700 includes one or more processors 702. The one or more processors control the operation of other components of the system / device 700. The one or more processors 702 may include, for example, a general purpose processor. The one or more processors 702 may be single-core or multi-core devices. The one or more processors 702 may include a central processing unit (CPU) or a graphical processing unit (GPU). Alternatively, the one or more processors 702 may include specialized processing hardware, such as a RISC processor or programmable hardware with embedded firmware. Multiple processors may be included.
[0092] The system / device includes a working or volatile memory 704. One or more processors may access the volatile memory 704 to process data and may control data storage in the memory. The volatile memory 704 may include any type of RAM, such as static RAM (SRAM), dynamic RAM (DRAM), or it may include a flash memory, such as an SD-card.
[0093] The system / apparatus includes a non-volatile memory 706. The non-volatile memory 706 stores a set of operating instructions 708 in the form of computer readable instructions for controlling the operation of the processor 702. The non-volatile memory 706 can be any type of memory, such as a read only memory (ROM), flash memory, or magnetic drive memory.
[0094] The one or more processors 702 are configured to execute operational instructions 708 to cause the system / device to perform any of the methods described herein. The operational instructions 708 may include code for hardware components of the system / device 700 (i.e., drivers), as well as code for basic operation of the system / device 700. Typically, the one or more processors 702 execute one or more instructions of the operational instructions 708, which are stored permanently or semi-permanently in the non-volatile memory 706, and the volatile memory 704 is used to temporarily store data generated during execution of said operational instructions 708.
[0095] Implementations of the methods described herein may be realized in digital electronic circuitry, integrated circuitry, specially designed ASICs (application specific integrated circuits), computer hardware, firmware, software, and / or combinations thereof, which may include a computer program product (e.g., software stored on a magnetic disk, optical disk, memory, programmable logic device, etc.) containing computer readable instructions that, when executed by a computer, cause the computer to perform one or more of the methods described herein, such as those described with respect to FIG.
[0096] System features described herein may also be provided as method features, and vice versa. As used herein, "means-plus-function" features may be expressed in terms of their corresponding structure. In particular, method aspects may also apply to system aspects, and vice versa.
[0097] Furthermore, any, some, and / or all of the features in one embodiment may also be applied to any, some, and / or all of the features in any other embodiment, in any appropriate combination. It is also to be understood that specific combinations of the various features described and defined in any embodiment of the present invention may be implemented and / or provided and / or used separately.
[0098] While several embodiments have been shown and described, those skilled in the art will understand that changes could be made to those embodiments without departing from the principles of the present disclosure, the scope of which is defined in the claims.
Claims
1. 1. A computer-implemented method for obtaining sequence information for each of a plurality of target multivalent immunoglobulin single variable domains (ISVs), comprising: receiving sequence information for each of a plurality of component ISVs, each target multivalent immunoglobulin single variable domain (ISV) comprising a plurality of said component ISVs; generating a set of candidate sequences for multivalent ISVs based on the received sequence information; obtaining a plurality of groups of reads of sequence information, each group of reads corresponding to a particular target multivalent ISV of the plurality of target multivalent ISVs; For each lead in the group of leads, identifying one or more hit candidate sequences from the set of candidate sequences, each of the one or more hit candidate sequences comprising a portion that matches a corresponding portion of the read; generating a consensus matrix for each of the candidate hit sequences using the candidate hit sequences, the reads, and one or more sequences derived from the reads, the consensus matrix defining, for each position among a plurality of positions in an aligned sequence, a consensus between the candidate hit sequences, the reads, and one or more sequences derived from the reads; generating an assembly matrix for each of the candidate hit sequences for each group of reads based on the consensus matrix for each read in the group of reads; Identifying sequence information for each target multivalent ISV based on one or more assembly matrices identified for the group of reads corresponding to the target multivalent ISV; Includes.
2. The read includes a character code for each position among the positions of the read, each character code being specified as either a primary base character code or an ambiguity character code, and identifying, for the read, one or more hit candidate sequences from the set of candidate sequences includes: removing one or more character codes from an end of the reads to generate shortened reads for each iteration among the multiple iterations; performing a pattern matching process between the truncated reads of an iteration and each candidate sequence; and if a truncated read of an iteration matches a particular candidate sequence, adding the particular candidate sequence to the one or more hit candidate sequences.
3. a read including a character code for each position among a plurality of positions of the read, each character code indicating either a key base character code or an ambiguity character code, the read indicating a sequencing quality for each position, and identifying, for a read, one or more hit candidate sequences from the set of candidate sequences includes: Receiving a cutoff parameter; identifying trimmed reads, the trimmed reads comprising removing one or more character codes from the reads, each of the reads having a sequencing quality lower than a value specified by the cutoff parameter; identifying a start position of the read; and removing character codes from the read before the start position; identifying a position in said read that first specifies an ambiguity character code; removing a character code from the read beginning at the identified position through a termination position of the read; The method of claim 1 or 2, comprising:
4. The method according to any one of claims 1 to 3, wherein each candidate sequence in the hit candidate sequences comprises a respective matching portion corresponding to each read in the group of reads.
5. The method of any one of claims 1 to 4, wherein the aligned sequences are identified by performing a multiple sequence alignment, MSA, between the hit candidate sequences, the reads, and one or more sequences derived from the reads.
6. 6. The method of claim 5, wherein the multiple sequence alignment is configured to align each of the hit candidate sequences, the reads, and each of the one or more sequences derived from the reads without introducing any gaps in the aligned sequences.
7. The one or more sequences derived from the reads include trimmed reads, each of which has one or more character codes removed that have a sequencing quality lower than a value specified by a received cutoff parameter; A base determination sequence, in which a position having an ambiguity character code of the read is replaced with a character code of a major base. The method according to any one of claims 1 to 6, comprising at least one of the following steps:
8. The method of any one of claims 1 to 7, wherein each group in the plurality of groups of reads comprises one or more forward reads for each of the target multivalent ISVs in the group and one or more reverse reads for each of the target multivalent ISVs.
9. generating a set of candidate sequences for multivalent ISVs based on the received sequence information, receiving sequence information for each of the one or more linkers; receiving an indication of a particular restriction enzyme recognition site; generating a set of candidate sequences for a multivalent ISV using the sequencing information of the one or more linkers and the representation of the specific restriction enzyme recognition sites; The method according to any one of claims 1 to 8, comprising:
10. The method of any one of claims 1 to 9, wherein the consensus matrix comprises a score for each major base letter code from major base letter codes at each position among the plurality of positions in the aligned sequences.
11. 11. The method of claim 10, wherein the assembly matrix includes, for each read in the group of reads and for each position in the aligned sequences, either a letter code for a major base or an empty symbol indicating that neither a major base nor a letter code could be identified at that position of the read.
12. 12. The method of any one of claims 1 to 11, wherein each component ISV is selected from a VL, a VH, a VHH, a humanised VHH and a camelised VH, and optionally each of said component ISVs is a multivalent ISV.
13. 13. The method of any one of claims 1 to 12, wherein the sequence information of each target multivalent ISV comprises a nucleic acid sequence, and / or the sequence information of each component ISV comprises a nucleic acid sequence, optionally wherein the nucleic acid sequence is a DNA sequence.
14. Apparatus comprising one or more processors configured to carry out the method of any one of claims 1 to 13.
15. A computer readable storage medium comprising instructions which, when executed by one or more processors, cause the one or more processors to perform the method of any one of claims 1 to 13.
16. 1. A computer device for obtaining sequence information for each of a plurality of target multivalent ISV immunoglobulin single variable domains (ISVs), comprising: receiving sequence information for each of a plurality of component ISVs, each target multivalent immunoglobulin single variable domain (ISV) comprising a plurality of said component ISVs; generating a set of candidate sequences for multivalent ISVs based on the received sequence information; obtaining a plurality of groups of sequencing information reads, each group of reads corresponding to a particular target multivalent ISV of the plurality of target multivalent ISVs; For each lead in the group of leads, Identifying one or more hit candidate sequences from the set of candidate sequences, each of the one or more hit candidate sequences comprising a matching portion with a corresponding portion of the read; generating a consensus matrix for each of the candidate hit sequences using the candidate hit sequences, the reads, and one or more sequences derived from the reads, the consensus matrix defining, for each position among a plurality of positions of the aligned sequences, a consensus between the candidate hit sequences, the reads, and one or more sequences derived from the reads; generating an assembly matrix of each hit candidate sequence for each group of reads based on the consensus matrix of each read in the group of reads; Identifying sequence information for each target multivalent ISV based on one or more assembly matrices identified for the group of reads corresponding to the target multivalent ISV; 23. An apparatus configured to:
